Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
Saved in:
| Title: | Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. |
|---|---|
| Authors: | Goodall RL; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK. Electronic address: r.goodall@ucl.ac.uk., Meredith SK; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Nunn AJ; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Bayissa A; Armauer Hansen Research Institute, Addis Ababa, Ethiopia., Bhatnagar AK; Rajan Babu Institute for Pulmonary Medicine & Tuberculosis, Delhi, India., Bronson G; Vital Strategies, New York, NY, USA., Chiang CY; Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; International Union against Tuberculosis and Lung Disease, Paris, France., Conradie F; Empilweni TB Hospital, Eastern Cape, South Africa., Gurumurthy M; Vital Strategies, Singapore., Kirenga B; Makerere University Lung Institute, Mulago Hospital, Kampala, Uganda., Kiria N; National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia., Meressa D; St Peter's Tuberculosis Specialized Hospital and Global Health Committee, Addis Ababa, Ethiopia., Moodliar R; Tuberculosis & HIV Investigative, Doris Goodwin Hospital, Pietermaritzburg, South Africa., Narendran G; National Institute for Research in Tuberculosis, Chennai, India., Ngubane N; King Dinuzulu Hospital Complex, Durban, South Africa., Rassool M; Clinical HIV Research Unit, Helen Joseph Hospital, Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa., Sanders K; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Solanki R; B J Medical College, Ahmedabad, India., Squire SB; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Torrea G; Institute of Tropical Medicine, Antwerp, Belgium., Tsogt B; Mongolian Tuberculosis Coalition, Ulaanbaatar, Mongolia., Tudor E; Institute of Phthisiopneumology Chiril Draganiuc, Chisinau, Moldova., Van Deun A; Institute of Tropical Medicine, Antwerp, Belgium., Rusen ID; Vital Strategies, New York, NY, USA. |
| Corporate Authors: | STREAM study collaborators |
| Source: | Lancet (London, England) [Lancet] 2022 Nov 26; Vol. 400 (10366), pp. 1858-1868. Date of Electronic Publication: 2022 Nov 08. |
| Publication Type: | Randomized Controlled Trial; Multicenter Study; Journal Article; Equivalence Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36368336 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Goodall+RL%22">Goodall RL</searchLink>; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK. Electronic address: r.goodall@ucl.ac.uk.<br /><searchLink fieldCode="AU" term="%22Meredith+SK%22">Meredith SK</searchLink>; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Nunn+AJ%22">Nunn AJ</searchLink>; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Bayissa+A%22">Bayissa A</searchLink>; Armauer Hansen Research Institute, Addis Ababa, Ethiopia.<br /><searchLink fieldCode="AU" term="%22Bhatnagar+AK%22">Bhatnagar AK</searchLink>; Rajan Babu Institute for Pulmonary Medicine & Tuberculosis, Delhi, India.<br /><searchLink fieldCode="AU" term="%22Bronson+G%22">Bronson G</searchLink>; Vital Strategies, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Chiang+CY%22">Chiang CY</searchLink>; Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; International Union against Tuberculosis and Lung Disease, Paris, France.<br /><searchLink fieldCode="AU" term="%22Conradie+F%22">Conradie F</searchLink>; Empilweni TB Hospital, Eastern Cape, South Africa.<br /><searchLink fieldCode="AU" term="%22Gurumurthy+M%22">Gurumurthy M</searchLink>; Vital Strategies, Singapore.<br /><searchLink fieldCode="AU" term="%22Kirenga+B%22">Kirenga B</searchLink>; Makerere University Lung Institute, Mulago Hospital, Kampala, Uganda.<br /><searchLink fieldCode="AU" term="%22Kiria+N%22">Kiria N</searchLink>; National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.<br /><searchLink fieldCode="AU" term="%22Meressa+D%22">Meressa D</searchLink>; St Peter's Tuberculosis Specialized Hospital and Global Health Committee, Addis Ababa, Ethiopia.<br /><searchLink fieldCode="AU" term="%22Moodliar+R%22">Moodliar R</searchLink>; Tuberculosis & HIV Investigative, Doris Goodwin Hospital, Pietermaritzburg, South Africa.<br /><searchLink fieldCode="AU" term="%22Narendran+G%22">Narendran G</searchLink>; National Institute for Research in Tuberculosis, Chennai, India.<br /><searchLink fieldCode="AU" term="%22Ngubane+N%22">Ngubane N</searchLink>; King Dinuzulu Hospital Complex, Durban, South Africa.<br /><searchLink fieldCode="AU" term="%22Rassool+M%22">Rassool M</searchLink>; Clinical HIV Research Unit, Helen Joseph Hospital, Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa.<br /><searchLink fieldCode="AU" term="%22Sanders+K%22">Sanders K</searchLink>; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Solanki+R%22">Solanki R</searchLink>; B J Medical College, Ahmedabad, India.<br /><searchLink fieldCode="AU" term="%22Squire+SB%22">Squire SB</searchLink>; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.<br /><searchLink fieldCode="AU" term="%22Torrea+G%22">Torrea G</searchLink>; Institute of Tropical Medicine, Antwerp, Belgium.<br /><searchLink fieldCode="AU" term="%22Tsogt+B%22">Tsogt B</searchLink>; Mongolian Tuberculosis Coalition, Ulaanbaatar, Mongolia.<br /><searchLink fieldCode="AU" term="%22Tudor+E%22">Tudor E</searchLink>; Institute of Phthisiopneumology Chiril Draganiuc, Chisinau, Moldova.<br /><searchLink fieldCode="AU" term="%22Van+Deun+A%22">Van Deun A</searchLink>; Institute of Tropical Medicine, Antwerp, Belgium.<br /><searchLink fieldCode="AU" term="%22Rusen+ID%22">Rusen ID</searchLink>; Vital Strategies, New York, NY, USA. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22STREAM+study+collaborators%22">STREAM study collaborators</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2022 Nov 26; Vol. 400 (10366), pp. 1858-1868. <i>Date of Electronic Publication: </i>2022 Nov 08. – Name: TypePub Label: Publication Type Group: TypPub Data: Randomized Controlled Trial; Multicenter Study; Journal Article; Equivalence Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36368336 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S0140-6736(22)02078-5 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1858 Titles: – TitleFull: Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Goodall RL – PersonEntity: Name: NameFull: Meredith SK – PersonEntity: Name: NameFull: Nunn AJ – PersonEntity: Name: NameFull: Bayissa A – PersonEntity: Name: NameFull: Bhatnagar AK – PersonEntity: Name: NameFull: Bronson G – PersonEntity: Name: NameFull: Chiang CY – PersonEntity: Name: NameFull: Conradie F – PersonEntity: Name: NameFull: Gurumurthy M – PersonEntity: Name: NameFull: Kirenga B – PersonEntity: Name: NameFull: Kiria N – PersonEntity: Name: NameFull: Meressa D – PersonEntity: Name: NameFull: Moodliar R – PersonEntity: Name: NameFull: Narendran G – PersonEntity: Name: NameFull: Ngubane N – PersonEntity: Name: NameFull: Rassool M – PersonEntity: Name: NameFull: Sanders K – PersonEntity: Name: NameFull: Solanki R – PersonEntity: Name: NameFull: Squire SB – PersonEntity: Name: NameFull: Torrea G – PersonEntity: Name: NameFull: Tsogt B – PersonEntity: Name: NameFull: Tudor E – PersonEntity: Name: NameFull: Van Deun A – PersonEntity: Name: NameFull: Rusen ID IsPartOfRelationships: – BibEntity: Dates: – D: 26 M: 11 Text: 2022 Nov 26 Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1474-547X Numbering: – Type: volume Value: 400 – Type: issue Value: 10366 Titles: – TitleFull: Lancet (London, England) Type: main |
| ResultId | 1 |